IASO Bio achieves 95 9 percent response rate in FUCASO study
Biopharmaceutical firm IASO Bio presented clinical trial results showing a 95 9 percent objective response rate for its FUCASO therapy in patients with relapsed plasma cell neoplasms
Shanghai, Nanjing, China, and Pleasanton, California - September 27, 2026 - IASO Biotechnology, a biopharmaceutical company concentrating on novel cell therapies for hematologic malignancies and autoimmune diseases, unveiled results from a real-world study of its first fully human BCMA-targeting CAR-T cell therapy, FUCASO, at the 2026 International Myeloma Society Annual Meeting.
The study, comprising 281 patients, showcased an impressive 95.9% objective response rate and a 77.2% complete response or stringent complete response rate. Although median progression-free and overall survival rates were not yet achieved at 10.97 months, the 12-month progression-free and overall survival rates stood at 71.5% and 87.8%, respectively.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
